What type of study is this?

September 29, 2025Cancer Research

Abstract A114: CCK-B Receptor Blockade with Proglumide Enhances Antitumor Activity and Persistence of CD8+CD161+ CAR-T Cells in Pancreatic Ductal Adenocarcinoma

View Full Paper

Ask AI

Bookmark

Authors

Combination therapy reduces tumor burden in PDAC, suggesting CCK-BR blockade may enhance CD8+CD161+ CAR-T cells.

Combination therapy significantly reduced tumor burden in pancreatic ductal adenocarcinoma models.
Results show improved overall survival rates with combination therapy compared to monotherapy.
Proglumide enhances infiltration of CAR-T cells into tumors, improving therapeutic outcomes.
This approach may help overcome fibrotic barriers in pancreatic ductal adenocarcinoma.

Bisht et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark